Skip to main content
Figure 1 | BMC Immunology

Figure 1

From: Iloprost modulates the immune response in systemic sclerosis

Figure 1

Iloprost reduces T cells. PBMCs isolated from SSc patients at baseline and after treatment with iloprost (5 days of daily treatment, 28 days after the last infusion) were analysed by flow cytometry to evaluate T cells, monocytes, TNF α production and degree of T cell activation. A. Graph shows the percentage of T cells (CD3+) and of monocytes (CD14+) among PBMCs. Bars represent mean and SD for all the patients, p values were calculated by a paired Student's t test, significant values are displayed. B. Graph shows the percentage of TNF α producing T cells (CD3+, gated on lymphocytes) and monocytes (CD14+, gated on monocytes). Bars represent mean and SD for all the patients, p values were calculated by a paired Student's t test, significant values are displayed. C. In vitro challenge of PBMCs culture with iloprost for 15 and 120 min. Graph shows the percentage of T cells (CD3+) in PBMCs. Bars represent mean and SD of five independent experiments. The reduction is not statistically significant.

Back to article page